Roivant Sciences Ltd.
ROIVPharmaceutical Preparations · SIC 2834 · CIK 0001635088
Revenue FY2026
$0.01B
Net Income
$(0.30B)
EPS (Basic)
$-0.43
Net Margin
-3629.2%
ROE
-6.6%
Total Equity
$4.53B
Shares Out
722M
Roivant Sciences Ltd. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2021–FY2026; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.
Revenue & Net Income (10Y)
Margin Trends
Investor Ownership · 7 funds in our universe
FundPosition Value% of AUMQoQ ChgWeight
Greenlight Capital (DME)
David Einhorn
$76.2M
1.6%
—
Platinum Investment Management
Platinum Investment Management
$3.3M
0.8%
—
Maverick Capital
Lee Ainslie
$100.1M
0.6%
+73.9%
Baker Bros. Advisors
Baker Bros. Advisors
$166.9M
0.6%
(3.1%)
Adage Capital Management
Adage Capital Management
$366.3M
0.5%
(19.1%)
Viking Global Investors
Andreas Halvorsen
$221.9M
0.3%
(5.7%)
Polen Capital Management
Polen
$0.3M
0.0%
NEW
Insider Transactions
Reading stored insider transactions…